Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR)
暂无分享,去创建一个
April D. Miller | S. Xirasagar | I. Macdougall | F. Locatelli | C. Bennett | O. Sartor | H. Thomsen | D. Mattison | K. Starko | S. Cowper | Z. Qureshi | P. Bookstaver | D. Cournoyer | S. Luminari | Adam Kahn | L. Norris | Charles L. Bennett | Alanna Murday | A. Trenery | I. Lopez | Paul S. Ray | Henrik S. Thomsen | P. Brandon Bookstaver | Karen M. Starko | Iain C. Macdougall | Donald R. Mattison
[1] I. Macdougall,et al. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. , 2012, Kidney international.
[2] S. Xirasagar,et al. Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease , 2012, Clinical kidney journal.
[3] I. Macdougall,et al. Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity , 2011, Pharmaceutical Research.
[4] Tim Wogan. Scientific publishing. A chilling effect? , 2010, Science.
[5] H. Koplik. The Diseases of Infancy and Childhood: Designed for the Use of Students and Practitioners of Medicine , 2010 .
[6] L. E. Holt,et al. The diseases of infancy and childhood : for the use of students and practitioners of medicine. , 2010 .
[7] I. Macdougall,et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. , 2009, The New England journal of medicine.
[8] M. Perazella. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm , 2009, Current opinion in nephrology and hypertension.
[9] L. Skov,et al. Nephrogenic systemic fibrosis: clinical picture and treatment. , 2009, Radiologic clinics of North America.
[10] H. Thomsen,et al. Nephrogenic systemic fibrosis: history and epidemiology. , 2009, Radiologic clinics of North America.
[11] Allen R Nissenson,et al. Epoetin‐associated pure red cell aplasia: past, present, and future considerations , 2008, Transfusion.
[12] P. Marckmann. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. , 2008, European journal of radiology.
[13] D. Stenver. Pharmacovigilance: what to do if you see an adverse reaction and the consequences. , 2008, European journal of radiology.
[14] L. Skov,et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] Lone Skov,et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. , 2006, Journal of the American Society of Nephrology : JASN.
[16] T. Grobner. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[17] R. Bucala,et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis--setting the record straight. , 2006, Seminars in arthritis and rheumatism.
[18] S. Belknap,et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2005, Blood.
[19] N. Casadevall,et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. , 2005, Kidney international.
[20] G. Wells,et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. , 2004, Journal of the American Society of Nephrology : JASN.
[21] Allen R Nissenson,et al. Pure red-cell aplasia and epoetin therapy. , 2004, The New England journal of medicine.
[22] Jeffrey B. Gross,et al. Timing of New Black Box Warnings and Withdrawals for Prescription Medications , 2003 .
[23] Patrick Mayeux,et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. , 2002, The New England journal of medicine.
[24] P. Leboit,et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients , 2000, The Lancet.
[25] R. Holman,et al. Reye's syndrome in the United States from 1981 through 1997. , 1999, The New England journal of medicine.
[26] J. G. Kennedy. Over the counter drugs , 1996, BMJ.
[27] P. Buffler,et al. Reduction of deaths after drug labelling for risk of Reye's syndrome , 1992, The Lancet.
[28] A. Feinstein,et al. New epidemiologic evidence confirming that bias does not explain the aspirin/Reye's syndrome association. , 1989, JAMA.
[29] P. Pinsky,et al. Reye's syndrome and aspirin. Evidence for a dose-response effect. , 1988 .
[30] D. Kennedy,et al. National patterns of aspirin use and Reye syndrome reporting, United States, 1980 to 1985. , 1987, Pediatrics.
[31] P. Pinsky,et al. Public Health Service study of Reye's syndrome and medications. Report of the main study. , 1987, JAMA.
[32] M. Tarlow. Reye's syndrome and aspirin. , 1986, British medical journal.
[33] R. Kaslow,et al. Public Health Service study on Reye's syndrome and medications. Report of the pilot phase. , 1985, The New England journal of medicine.
[34] J. Glasgow. Reye’s Syndrome , 1985, Drug safety.
[35] F. Suchy,et al. Grade I Reye's syndrome. A frequent cause of vomiting and liver dysfunction after varicella and upper-respiratory-tract infection. , 1983, The New England journal of medicine.
[36] F. Mullick,et al. HEPATIC AND CEREBRAL PATHOLOGY FINDINGS IN CHILDREN WITH FATAL SALICYLATE INTOXICATION: FURTHER EVIDENCE FOR A CAUSAL RELATION BETWEEN SALICYLATE AND REYE'S SYNDROME , 1983, The Lancet.
[37] W. Glezen. Aspirin and Reye's syndrome. , 1982, American journal of diseases of children.
[38] R. Waldman,et al. Aspirin as a risk factor in Reye's syndrome. , 1982, JAMA.
[39] J. Cherry,et al. Aspirin and Reye Syndrome , 1982, Pediatrics.
[40] K. Starko,et al. Reye's syndrome and salicylate use. , 1980, Pediatrics.
[41] Moshe Y. Vardi,et al. ACUTE DELIRIOUS STATE AFTER ϵ-AMINOCAPROIC ACID , 1978, The Lancet.
[42] J. Korf,et al. DOPAMINE AND SCHIZOPHRENIA , 1976, The Lancet.
[43] G. Morley. ASBESTOS IN THE AIR , 1976, The Lancet.
[44] V. Hawthorne,et al. SCREENING FOR DISEASE , 1975, The Lancet.
[45] W. Schubert,et al. Mitochondrial ultrastructure in Reye's syndrome (encephalopathy and fatty degeneration of the viscera). , 1971, The New England journal of medicine.
[46] H. Giles. ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA. , 1965, Lancet.
[47] R. Reye,et al. ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA , 1963 .
[48] R. Reye,et al. ENCEPHALOPATHY AND FATTY DEGENERATION OF THE VISCERA. A DISEASE ENTITY IN CHILDHOOD. , 1963, Lancet.
[49] E. Mortimer,et al. Varicella with hypoglycemia possibly due to salicylates. , 1962, American journal of diseases of children.
[50] W. Segar,et al. Physiologic abnormalities of salicylate intoxication. , 1958, The New England journal of medicine.
[51] H. D. Riley,et al. Salicylate intoxication. , 1956, Pediatrics.
[52] K. Bain. Death due to accidental poisoning in young children. , 1954, The Journal of pediatrics.
[53] W. Parker,et al. The toxic manifestations of sodium salicylate therapy. , 1948, The Quarterly journal of medicine.
[54] Haub. Salicylate intoxication in the infant and young child , 1947 .
[55] R. Wégria,et al. Salicylate therapy in acute rheumatic fever , 1945 .
[56] F. Collins. Diseases of Infancy and Childhood , 1938, The Indian Medical Gazette.
[57] W. R. Brain,et al. ACUTE MENINGO-ENCEPHALOMYELITIS OF CHILDHOOD. , 1929 .
[58] P. Hanzlik. A study of the toxicity of the salicylates based on clinical statistics , 1913 .
[59] K. Eckardt,et al. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. , 2012, Clinical nephrology.
[60] R. Campbell,et al. Reye's syndrome and medication use. , 1982, JAMA.
[61] Surgeon General's advisory on the use of salicylates and Reye syndrome. , 1982, MMWR. Morbidity and mortality weekly report.
[62] Reye syndrome--Ohio, Michigan. , 1981, Connecticut medicine.